3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
Viking Therapeutics deserves a second look, but some analysts are a bit too optimistic.
Overview
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, is slightly in the red year-to-date. But the good news is that it has important catalysts over the next year or so that could send its share price soaring. How much will Viking Therapeutics gain in the next 12 months? That depends on which analysts you ask, and some are particularly bullish on the stock.
For instance, Steven Seedhouse, an analyst at Cantor Fitzgerald, has a $100 price target on the stock, implying it could roughly triple from current levels. At least two others, Jay Olson at Oppenheimer and Joseph Pantginis at HC Wainwright, also have price targets in the same range. Could Viking Therapeutics really triple in the next year? I don't think so. Here is why.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.